Results 11 to 20 of about 16,634 (253)

First‐line treatment of osteoporosis with osteoanabolic therapy: a new opportunity [PDF]

Internal Medicine Journal, Volume 55, Issue 8, Page 1232-1241, August 2025.
Abstract Osteoporosis is a national health priority, and over six million Australians over the age of 50 years have poor bone health. Fragility fractures due to osteoporosis are associated with an increased morbidity and mortality risk and a high economic cost to the community. It is a chronic condition requiring long‐term management.
Jasna Aleksova, Peter Ebeling
wiley   +2 more sources

A Phase 3 Multicenter, Double‐Blind Study Comparing Efficacy, Safety, Immunogenicity, and Pharmacokinetics of Alkem's Biosimilar Teriparatide Versus Reference Teriparatide in Postmenopausal Osteoporosis [PDF]

Aging Medicine
Objective The primary purpose of this study was to compare the efficacy and safety of proposed biosimilar teriparatide with reference teriparatide in patients of postmenopausal osteoporosis.
Nitin Kapoor, Thomas Paul, Rajeshwar Nath Srivastava, Saurabh Singh, Sunil Maheshwari, Vishal Patil, Awadhesh Kumar Yadav, Girish Bhatia, Sushil H. Mankar, Joe Joseph Cherian, Surabhi Maheshwari, Sudeepti Srivastava, Dattatray Pawar, Roshan Pawar, Amol Aiwale, Amitrajit Pal, Yogesh Rane, Vinayaka Shahavi, Akhilesh Sharma   +18 more
doaj   +2 more sources

Utilization and expenditure on medicines for the management of osteoporosis in Ireland: A repeated cross‐sectional study [PDF]

British Journal of Clinical Pharmacology, Volume 91, Issue 8, Page 2283-2293, August 2025.
Aim Osteoporosis is a prevalent skeletal disease characterized by low bone mass and increased fracture risk. Management of osteoporosis typically involves antiresorptive and anabolic therapies, which are reimbursed in Ireland through various drug schemes.
Amelia Smith, Lisa Kelly, Claire Gorry, Bernard Duggan, Michael Barry   +4 more
wiley   +2 more sources

Teriparatide mitigates oxidative stress following spinal cord injury and enhances neurological recovery via the Nrf2/HO-1 signaling pathway [PDF]

Frontiers in Pharmacology
IntroductionSpinal Cord Injury (SCI) represents a devastating form of central nervous system trauma, where oxidative stress plays a critical role in the ensuing pathology. Targeting oxidative stress presents a viable therapeutic avenue.
Xiong Moliang, Ai Gangtong, Feng Yun, Luo Caiguang, Deng Liang, Guo Jia, Xiao Qiang   +6 more
doaj   +2 more sources

Patient willingness to take teriparatide [PDF]

Patient Education and Counseling, 2006
Teriparatide [rhPTH (1-34)] is an effective treatment for osteoporosis administered by daily subcutaneous injection. The objective of this study was to determine how much benefit women expect teriparatide to confer before agreeing to perform daily injections.We recruited postmenopausal women who had recently undergone bone densitometry and were found ...
Liana Fraenkel, Barbara Gulanski, Dick R. Wittink   +2 more
openalex   +4 more sources

Chronic hypoparathyroidism and treatment with teriparatide [PDF]

Endocrine, 2021
Abstract Purpose Chronic hypoparathyroidism is usually treated with calcium and active vitamin D metabolites or analogs, despite the fact that their chronic use can lead to long-term complications. The use of hormone replacement therapy with PTH peptides [teriparatide and rhPTH (1–84)] has therefore been proposed.
Marcucci G., Masi L., Cianferotti L., Giusti F., Fossi C., Parri S., Gronchi G., Brandi M. L.   +7 more
openaire   +3 more sources

Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis [PDF]

Obstetrical & Gynecological Survey, 2007
Bisphosphonate therapy is the current standard of care for the prevention and treatment of glucocorticoid-induced osteoporosis. Studies of anabolic therapy in patients who are receiving long-term glucocorticoids and are at high risk for fracture are lacking.In an 18-month randomized, double-blind, controlled trial, we compared teriparatide with ...
Kenneth G. Saag, Elizabeth Shane, Steven Boonen, Fernando Marín, David W. Donley, Kathleen A. Taylor, G. P. Dalsky, Robert Marcus   +7 more
openalex   +5 more sources

Treatment of osteoporosis with teriparatide: The Slovenian experience [PDF]

Open Medicine, 2021
Abstract The aim of this study was to investigate the characteristics of postmenopausal women prescribed with teriparatide in Slovenia, during the first decade after its approval, and the predictors of bone mineral density (BMD) improvement with treatment.
Antonela Sabati Rajic, Nina Orehek, Barbara Ostanek, Mojca Jensterle Sever, Mojca Jensterle Sever, Gaj Vidmar, Gaj Vidmar, Janja Marc, Tomaz Kocjan, Tomaz Kocjan, Andrej Janez, Andrej Janez   +11 more
openaire   +4 more sources

Adjuvant pharmacological strategies for the musculoskeletal system during long‐term space missions

British Journal of Clinical Pharmacology, EarlyView., 2023
Abstract Despite 2 h of daily exercise training, muscle wasting and bone loss are still present after 6‐month missions to the international space station. Some crew members lose bone much faster than others. In preparation for missions to the Moon and Mars, space agencies are therefore reviewing their countermeasure portfolios.
Friederike Thomasius, Dominik Pesta, Jörn Rittweger   +2 more
wiley   +1 more source

The combined effect of parathyroid hormone (1–34) and whole-body vibration exercise on physical performance in OSteoporotic women (PaVOS study): a secondary analysis from a randomised controlled trial

BMC Sports Science, Medicine and Rehabilitation, 2020
Background The aim of this study was to investigate the effect on physical performance of combining whole-body vibration exercise (WBV) with parathyroid hormone 1–34 (teriparatide) compared to teriparatide alone.
Ditte Beck Jepsen, Tahir Masud, Anders Holsgaard-Larsen, Stinus Hansen, Niklas Rye Jørgensen, Jesper Ryg   +5 more
doaj   +1 more source